How Drug Cos. Can Adapt To New Reference Pricing Rules
Law360 (March 5, 2021, 6:08 PM EST) -- The final days of the Trump administration were marked by the publication of a flurry of drug pricing regulations, among the most controversial of which was a regulation that would have purported to test a new most-favored-nations reimbursement mechanism for the top 50 physician-administered prescription medicines paid for under Medicare Part B.
While the regulation is now on hold, it is the most significant attempt to date to use reference pricing to control drug spending. Unfortunately, the attempted implementation of this most-favored-nations regulation may normalize policy discussions in the U.S. around aggressive price control measures for prescription drugs, making such policies...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!